Quantbot Technologies LP Denali Therapeutics Inc. Transaction History

Quantbot Technologies LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 07, 2022	BUY	$25.97 - $38.53 $75,313 - $111,737	2,900 Added 362.5%	3,700 $113,000
Q2 2022 Aug 09, 2022	BUY	$20.88 - $35.19 $13,217 - $22,275	633 Added 379.04%	800 $23,000
Q1 2022 May 16, 2022	SELL	$29.0 - $47.27 $103,675 - $168,990	-3,575 Reduced 95.54%	167 $5,000
Q4 2021 Feb 11, 2022	BUY	$42.59 - $55.02 $141,015 - $182,171	3,311 Added 768.21%	3,742 $166,000
Q3 2021 Nov 09, 2021	SELL	$48.48 - $78.23 $42,420 - $68,451	-875 Reduced 67.0%	431 $21,000
Q2 2021 Aug 12, 2021	SELL	$50.3 - $78.44 $292,896 - $456,756	-5,823 Reduced 81.68%	1,306 $102,000
Q1 2021 May 14, 2021	BUY	$53.8 - $81.53 $383,540 - $581,227	7,129 New	7,129 $407,000
Q4 2020 Feb 12, 2021	SELL	$36.89 - $93.56 $109,969 - $278,902	-2,981 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$23.13 - $38.84 $68,950 - $115,782	2,981 New	2,981 $106,000
Q1 2020 May 13, 2020	SELL	$14.2 - $27.98 $63,573 - $125,266	-4,477 Closed	0 $0
Q4 2019 Feb 10, 2020	BUY	$14.4 - $19.99 $64,468 - $89,495	4,477 New	4,477 $77,000

227

119M

60.6K

48.4K

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $2.88B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

Get notified when there are updates to the investment portfolio of Quantbot Technologies LP, based on Form 13F filings with the SEC.

Stay updated on Quantbot Technologies LP with notifications on news.